DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06849050

ACECRAVE

CompletedPhase NA

The Influence of Acute Continuous Exercise and Adiposity on Appetite Hormones and Neural Correlates of Visual Food Cues

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

40

actual

Study population

Healthy volunteers, Obesity / overweight

Key I/E criterion

•BMI 18.5-24.9

Primary endpoint

•Plasma concentration (steady state)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06849050
Org study ID18581

Timeline

Milestones

Study start2024-07-05actual
Study first posted2025-02-27actual
Primary completion2025-09-03actual
Study completion2025-09-03actual
Last update posted2025-09-10actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteersObesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
Maximum age60 Years
SexAll
Healthy volunteersAccepted

Inclusion criteria

•Body mass index (BMI) between 18.5 - 24.9 kg/m2 and a waist circumference of ≤ 88 cm for women, and ≤ 102 cm for men or a BMI between 25 - 40 kg/m2 and a waist circumference of > 88 cm for women, and > 102 cm for men. BMI and waist circumference thresholds vary amongst ethnicities. People with a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family background are prone to central adiposity and their cardiometabolic risk occurs at a lower BMI. Therefore, the following BMI and waist circumference thresholds will be applied for people of South Asian, other Asian, Black African and African-Caribbean ethnicity: (1) BMI 18.5 kg/m2 to 23 kg/m2 and waist circumference of < 90 cm for men and < 80 cm for women; (2) BMI 23.1 kg/m2 to 40 kg/m2 and waist circumference of ≥ 90 cm for men and ≥ 80 cm for women.
•Normally consumes three meals a day
•Able to walk continuously for 1 hour on a treadmill
•Weight stable for 3 months (< 3kg change in weight)
•Regular menstrual cycle for the last 6 months (people taking the combined contraceptive pill are eligible for the study)
•Able to undergo a 45-minute MRI scan

Exclusion criteria

•Smokers (vaping is considered smoking in this study)
•Known medical conditions (e.g. diabetes, heart condition)
•Taking any medication which may affect the study outcomes (e.g. liraglutide, semaglutide, insulin, steroids, anti-psychotics)
•Clinically diagnosed eating disorder
•Previous bariatric surgery (e.g. gastric bypass, gastric band, sleeve gastrectomy)
•Food allergies or intolerances, or severe dislikes to study foods
•Pregnant or breastfeeding
•Have recently donated blood (within eight weeks of visits 2 and 3).

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other (unclassified)
4
Other clinical outcomes
3
Safety / tolerability / PK
2
Glycemic / diabetes
1
Cardiometabolic biomarkers
1
Patient-reported / QoL
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Concentration of Glucose

Time frame:Blood samples to measure glucose are collected at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours and 4 hours) in each trial.

concentration, descriptive

Cardiometabolic biomarkers

1 endpoint
Secondary/protocol endpoint

Concentration of Leptin

Time frame:Blood samples to measure leptin are collected at 0 hours [08:30] in each trial.

Leptin, change

concentration, descriptive

Patient-reported / QoL

1 endpoint
Secondary/protocol endpoint

Visual analogue score (VAS) for subjective appetite

Time frame:VAS is measured at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours, 4 hours and 4.5 hours) in each trial.

descriptive

Safety / tolerability / PK

2 endpoints
Primary/protocol endpoint

Concentration of Oxyntomodulin

Time frame:Blood samples to measure oxyntomodulin are collected at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours and 4 hours) in each trial.

Plasma concentration (steady state)

concentration, descriptive

Secondary/protocol endpoint

Concentration of Glucagon-like peptide 1

Time frame:Blood samples to measure GLP-1 are collected at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours and 4 hours) in each trial.

concentration, descriptive

Other clinical outcomes

3 endpoints
Secondary/protocol endpoint

Gustatory perceptions

Time frame:The taste tests will take place at three time points during the trials: 0 hours [08:30], 1.5 hours and 4 hours.

descriptive

Secondary/protocol endpoint/low confidence

Olfactory perceptions

Time frame:The smell tests will take place at three time points during the trials: 0 hours [08:30], 1.5 hours and 4 hours.

descriptive

Secondary/protocol endpoint/low confidence

Task-based fMRI

Time frame:45-minute scan at baseline

descriptive

Other (unclassified)

4 endpoints
Secondary/protocol endpoint/low confidence

Concentration of Acylated Ghrelin

Time frame:Blood samples to measure acylated ghrelin are collected at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours and 4 hours) in each trial.

concentration, descriptive

Secondary/protocol endpoint/low confidence

Concentration of Peptide YY

Time frame:Blood samples to measure PYY are collected at 30-minute intervals (0 hours [08:30], 0.5 hours, 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours and 4 hours) in each trial.

concentration, descriptive

Secondary/protocol endpoint/low confidence

Energy intake

Time frame:The ad libitum pasta meal is provided at 2.5 hours (11:00)

descriptive

Secondary/protocol endpoint/low confidence

Resting state fMRI

Time frame:45-minute scan at baseline

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.